Meeting
2017 ASCO Annual Meeting
Phase II trial of bevacizumab and temozolomide for upfront treatment of elderly patients with newly diagnosed glioblastoma.
Authors
Phioanh Leia Nghiemphu
University of California, Los Angeles, Los Angeles, CA
Phioanh Leia Nghiemphu , Hye Hyun Bahng , Albert Lai , Nadia Faiq , William H. Yong , Richard M. Green , Jonathan Polikoff , Cynthia Elizabeth Spier , Fabio Massaiti Iwamoto , Andrew B. Lassman , Timothy Francis Cloughesy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01149850
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2012)
DOI
10.1200/JCO.2017.35.15_suppl.2012
Abstract #
2012
Poster Bd #
254
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase II trial of bevacizumab and temozolomide for treatment of elderly patients with newly diagnosed glioblastoma.
First Author: Donna Molaie
Poster
2013 ASCO Annual Meeting
BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation.
First Author: Jeffrey J. Raizer
Poster
2013 ASCO Annual Meeting
Temozolomide plus bevacizumab in elderly patients with newly diagnosed glioblastoma and poor performance status: An Αnocef phase II trial.
First Author: German Reyes-Botero
Poster
2011 ASCO Annual Meeting
Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
First Author: A. M. P. Omuro